A group of Chilean investors has acquired Farmacias Ahumada
October 2023 — A group of Chilean investors has acquired Farmacias Ahumada S.A. from Walgreens Boots Alliance.
The acquisition is carried out by a selected group of non-institutional chilean investors.
Founded in 1968, Farmacias Ahumada operates as one of the three main pharmaceutical chains in Chile, with almost 300 drugstores. It offers a range of products and services, such as drugs, natural products, nutritional supplements and beauty items and personal care products. The company is based in Santiago.
Walgreens Boots Alliance is an American public multinational holding headquartered in Illinois. It is an integrated healthcare, pharmacy and retail leader, which owns the pharmacy chains Walgreens in the US and Boots in the UK and internationally, as well as the Benavides brand in Mexico.
Our role in the transaction
Oaklins’ team in Chile advised a group of Chilean investors on the acquisition of Farmacias Ahumada.
Talk to the deal team
Related deals
Mattina Holding has sold a 5% stake in Gens Aurea via accelerated bookbuild
Mattina Holding S.A. (DVC Partners) has sold a 5% stake in Italian company Gens Aurea S.p.A. through an accelerated bookbuild, raising approximately US$69.96 million.
Learn moreTNT has been acquired by PM Studio
TNT Group has been acquired by PM Studio Group, backed by Andera Partners, bringing together two complementary specialists in premium packaging for the beauty and luxury industries. TNT’s expertise in bespoke primary packaging complements PM Studio’s secondary packaging, gifting and creative design capabilities, creating a broader, integrated offering for major luxury brands. The transaction strengthens the group’s geographical footprint in Asia and the USA, diversifying its customer portfolio. The combined group generates over US$145 million in revenue and has approximately 150 employees worldwide. Following the transition of operational leadership to CEO Damon Kennish, the founders completed the sale to PM Studio while making a significant reinvestment alongside the management team, demonstrating their confidence in the combined group’s long-term potential. It aims to reach US$280 million in revenue by 2029 through organic growth, commercial synergies and further acquisitions.
Learn moreKatalyst Diagnostics has been acquired by Cruinn Diagnostics
Katalyst Diagnostics Ltd. has been acquired by Cruinn Diagnostics Ltd. The acquisition strengthens Cruinn Diagnostics’ presence in the UK diagnostics market, adding established NHS customer relationships, local commercial infrastructure and a complementary portfolio of point-of-care diagnostic solutions. It also creates opportunities to introduce Cruinn Diagnostics’ products to UK customers while leveraging its established Irish platform to accelerate the growth of Katalyst Diagnostics’ portfolio in Ireland. With more than 100 employees and revenues in excess of US$56 million, the combined business will continue to focus on the UK market, where Cruinn Diagnostics sees significant opportunities to expand through further investment and targeted M&A.
Learn more